Interaksi Kalium klorida

Potassium chloride is contraindicated in patients on triamterene and amiloride. (label Kalium klorida, Kontraindikasi)

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (label Eplerenon, Kontraindikasi)

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (label Glikopironium, Interaksi obat)

Solid dosage forms of potassium chlorides have produced stenotic and/or ulcerative lesions of the small bowel and deaths. (label Kalium sitrat, Peringatan dan perhatian)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (label Spironolakton dan hidroklorotiazid, Perhatian)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (label Kalium klorida, Kontraindikasi)

Potassium chloride is contraindicated in patients on triamterene and amiloride. (label Kalium klorida, Kontraindikasi)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (label Aliskiren, Peringatan dan perhatian)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (label Amlodipin dan benazepril, Peringatan dan perhatian)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (label Amlodipin dan valsartan, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Benazepril, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (label Enalapril, Peringatan dan perhatian)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (label Enalapril dan hidroklorotiazid, Interaksi obat)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (label Enalaprilat, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Monitor serum potassium levels; use potassium supplements if necessary. (label Fludrokortison, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (label Fosinopril, Interaksi obat)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (label Fosinopril dan hidroklorotiazid, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (label Irbesartan dan hidroklorotiazid, Peringatan dan perhatian)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (label Kalium iodida, Interaksi obat)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (label Kandesartan, Interaksi obat)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (label Kandesartan dan hidroklorotiazid, Interaksi obat)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (label Kaptopril, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (label Lisinopril, Peringatan dan perhatian)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (label Lisinopril dan hidroklorotiazid, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (label Moeksipril, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (label Olmesartan, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (label Perindopril, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (label Sakubitril dan valsartan, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (label Siklosporin, Interaksi obat)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (label Spironolakton, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (label Telmisartan, Peringatan dan perhatian)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (label Telmisartan dan amlodipin, Peringatan dan perhatian)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (label Trandolapril, Interaksi obat)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (label Valsartan, Interaksi obat)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (label Valsartan dan hidroklorotiazid, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (label Bumetanid, Peringatan)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (label Dobutamin, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (label Hiosiamin, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (label Milrinon, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (label Kalium klorida, Interaksi obat)